Manager-Analytical Development

You will be joining Jubilant Pharma Limited, a global integrated pharmaceutical company offering a wide range of products and services worldwide. The company is structured into two key segments: Specialty Pharmaceuticals and Generics & APIs. - In the Specialty Pharmaceuticals segment, you will have the opportunity to work on Radiopharmaceuticals, Contract Manufacturing of Sterile Injectable, Non-sterile & Allergy Therapy Products. - In the Generics & APIs segment, your focus will be on Solid Dosage Formulations & Active Pharmaceutical Ingredients. Jubilant Generics (JGL), a subsidiary of Jubilant Pharma, has Research & Development units located in Noida and Mysore, India. JGL operates manufacturing facilities in Mysore, Karnataka, and Roorkee, Uttarakhand, dedicated to APIs and Dosage manufacturing. - You will be part of a team that operates the Mysore manufacturing site, which is USFDA approved and produces APIs for global distribution, with a focus on Lifestyle driven Therapeutic Areas such as CVS and CNS. - Additionally, you may contribute to the Roorkee facility, which is a state-of-the-art site catering to B2B markets in EU, Canada, and emerging markets, approved by multiple regulatory bodies including USFDA, Japan PMDA, UK MHRA, TGA, WHO, and Brazil ANVISA. The backward-integrated manufacturing units are supported by a team of 500 research and development professionals based in Noida and Mysore. The R&D team focuses on developing new products in API, Solid Dosage Formulations, Sterile Injectable products, Semi-Solids like Ointments, Creams, and Liquids, conducting all BA/BE studies in-house at an 80 Bed facility with global regulatory accreditations. - You will have the opportunity to work with Regulatory Affairs & IPR professionals managing a unique portfolio of patents and product filings for regulatory and non-regulatory markets. Jubilant Pharma has witnessed consistent revenue growth, with revenue reaching INR 53,240 Million in the Financial Year 2018-19, compared to INR 39,950 Million in the Financial Year 2017-18. If you are interested in learning more about the organization, please visit www.jubilantpharma.com.,